What year was the pharmaceutical company that markets Mylotarg purchased by Pfizer?
Gemtuzumab ozogamicin Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies. It was re-introduced into the US market in 2017.
Chugai Pharmaceutical Co. Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社 , Chūgai Seiyaku Kabushikigaisha ) is a subsidiary drug manufacturer operating in Japan controlled by Hoffmann–La Roche, which owns 62% of the company as of 30 June 2014. Previous to Roche's takeover in 2002, Chugai was a pioneering discoverer of many important pharmaceutical compounds. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director, chairman, and CEO. Tatsuro Kosaka is the current representative director, president, and COO.